It will be more than a year for the U.S. healthcare industry to return to normal, with physicians expecting the new normal to be sometime around August 2021—once a vaccine for COVID-19 has been distributed.

The rule eliminates provisions of a 2016 rule from the Obama administration that attempted to protect trans patients from discrimination.

Kaiser Permanente is among a handful of major healthcare organizations that have promised to refund the government millions in aid meant to help health systems and hospitals deal with the COVID-19 pandemic.

Reports of sky-high costs for coronavirus testing may be the exception, with the majority of testing being “relatively tame” in cost, according to an analysis by Axios.

President Trump has stated he wants to terminate the United States’ relationship with the World Health Organization.

CVS Health has been accused of overcharging for generic medications in a new lawsuit brought forth by six Blue Cross Blue Shield plans.

More than 1,750 standalone Medicare Part D prescription drug plans and MA plans have applied to offer insulin at a maximum $35 copay for a month’s supply of the drug for the 2021 plan year, CMS announced.

The healthcare sector has seen an influx of funding from private equity groups over the last several years, aiding in the contraction of the industry. But has the influence of cash been beneficial for healthcare?